GlobeNewsWire
04 Jun 2026, 20:37 UTC · 14w ago
Verdict
Headline takes no side. We score TPST +0.30 across two claims — moderately bullish.
+0.30moderately bullish
More positive than 60% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Tempest Therapeutics has developed a portfolio of CAR-T cell therapy product candidates for advanced cancers.
More positive than 65% of claims this week
Tempest Therapeutics appointed Drake Richey and Dr. John Yee to its Board of Directors.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 46% of claims this week
Which stocks this story touches
More positive than 60% of ticker scores this week
The company appointed two experienced independent directors to its board to support growth and capital allocation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1h ago
−41.9%
Price is moving against the score
$0.7554 vs $1.30 close before publication (Jun 4) · not market-adjusted
TPST chart →
